Company News 20 Oct 2025 Orthocell secures global distribution rights to innovative bone regeneration technology Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical - from 1.7% to 12.0% for… Orthocell
Company News 17 Oct 2025 $30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement. Orthocell
Company News 10 Oct 2025 Quarterly Report – period ended 30 September 2025 Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth… Orthocell
Company News 02 Oct 2025 Orthocell Announces Record Revenue of $3m for September Quarter Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record… Orthocell
Company News 30 Sep 2025 Orthocell Appoints First Distributor for Remplirâ„¢ in US$75m Canadian Market Orthocell has appointed its first Canadian distributor for Remplirâ„¢, signalling the commencement of the Company’s commercial roll out in the… Orthocell
Media 26 Sep 2025 STOCKHEAD | Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market Orthocell was featured in a Stockhead article by leading biotech journalist Tim Boreham titled “Orthocell flags rapid ‘hockey stick’ revenue… Orthocell
Company News 16 Sep 2025 Global opportunity emerges as Remplirâ„¢ is used in nerve-sparing prostate cancer surgery Orthocell has identified a promising new application for its flagship Remplirâ„¢ nerve repair device - for use in nerve-sparing Robotic-Assisted… Orthocell
Company News 08 Sep 2025 Remplirâ„¢ Real World Evidence study delivers compelling 81% success rate Orthocell has today released interim results from a new Remplirâ„¢ Real World Evidence study, demonstrating an overall treatment success rate… Orthocell
Company News 13 Aug 2025 Commercialisation of Remplirâ„¢ into US Market Continues to Build Momentum Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplirâ„¢ in the US. Orthocell
Company News 25 Jul 2025 Orthocell Announces Changes to its Board of Directors Orthocell has today announced some important changes to its Board of Directors. Orthocell
